在心力衰竭心脏中高度表达的特点,采用反义策略检测发现在Dahl-盐敏感大鼠中periostin的表达是受抑制的.同样重要的是,periostin基因的表达受抑制可导致在大鼠的存活率显著增加,同时伴随LV功能的改善.结论本研究证实了在动物模型中periostin基因与心脏扩张的因果关系,抑制periostin表达可能成为心力衰竭治疗的新策略之一.Thus,weexaminedtheinhibitionofperiostininDahlsalt-sen-sitiveratsbyanantisensestrategybecauseperiostinishighlyex-pressedinheartfailure.Importantly,inhibitionofperiostingeneexpressionresultedinasignificantincreaseinsurvivalrate,ac-companiedbyanimprovementofLVfunction.Conclusion—Thepresentstudydemonstratedthecontribu-tionoftheperiostingenetocardiacdilationinanimalmodels.Inhibitionofperiostinmightbecomeanewtherapeutictargetforthetreatmentofheartfailure.分子检测的影响:心脏移植患者从新技术、早期监测中获益对心脏移植患者采用的新技术通过一项简单的血液检测就提示患者器官排斥的风险.这种革命性检测方法出现的消息将在费城举行的国际心肺移植学会(ISHLT)年会和科学会议上公布.这一突破性的分子检测方法是非侵入性的,将复杂的免疫系统多基因信号和通路翻译成客观的可操作的积分.联合对病人免疫系统的早期监测,内科医生现在能够运用这种检测方法在排斥反应和组织破坏出现之前就识别之.关于ISHLT国际心肺移植学会是一个非赢利性组织,致力于科学的进步和心肺疾病终末期的治疗.该学会创立于1981年,目前包括来自于45个国家的2200多个成员,涉及到了关于终末期心肺疾病管理和治疗的众多领域.ISHLT维护两个重要的数据库.国际心肺移植登记处是众多类似组织中的一种,正在收集18个国家223家医院自1983年以来的数据.ISHLT机械循环装置数据库(MCSD)则在收集2002年以来的数据,目的是识别可能从MCSD植入中获益的病人群,生成预后的预测模型,评估目前和未来装置的机械和生物可靠性.Moleculartestingimpact:Hearttransplantpatientsbenefitformnewtechnology,easiermonitoringPresentationsatISHLTmeetingtodayNewtechnologyforcardiactransplantpatientsindicatesapatient'sriskoforganrejectionwithasimplebloodtest.NewofthisrevolutionarytestingmethodwillbepresentedtodayattheInternationalSocietyforHeartandLungTransplantation's(ISHLT)AnnualMeetingandScientificSessioninPhiladelphia.Thisbreakthroughinmoleculartestingisanon-invasivemethodthattranslatesthecomplessignalsoftheimmunesys-tem'smultiplegenesandpathwaysintoanobjective,avtionablescore.Alongwithproactivemonitoringofthepatient'simmunesystemm,physicianscannowusethistesttoidentifyrejectionandtissuedamagebeforeitoccurs.AboutISHLTTheInternationalSocietyforHeartandLungTransplanta-tion(ISHLT)isanot-for-profitorganizationdedicatedtotheadvancementofthescienceandtreatmentofend-stageheartandlungdiseases.Createdin1981,theSocietynowincludesnorethan2,200membersfrom45-pluscountries,represseningavarietyofdisciplinesinvolvedingthemanagementandtreat-mentofend-stageheartandlungdisease.ISHLTmaintainstwovitaldatabases.TheInternationalHeartandLungTransplantRegistryisanoe-of-a-kindregistrythathasbeencollectingdatasince1983form223hospitalsform18conuntries.TheISHLTMechanicalCirculatoryDeveice＊MCSD)databasehasbeencollectingdatasince2002withtheaimofidentfyingpatientpopulationswhomaybenefitformMCSDimplantation;generatingpredictivemodelsforoutcomes;andassessingthemechanicalandbiologicalreliabilityofcurrentandfuturedeveices.Formorein-formation.546JournalofModernClinicalMedicalBioengineering2005,Vol.11,No.6
